Dataset Information

EEF2K activity determines synergy to PI3K and MEK inhibitors in combination in cancer cells

ABSTRACT: To understand the mechanisms involved in synergy to PI3Ki + MEKi treatment, we performed a global phosphoproteomics analysis in 3 different cancer cell lines treated with a MEK inhibitor (Trametinib) and a PI3K inhibitor (Pictilisib) at 500 nM individually or in combination for one hour.

INSTRUMENT(S): Q Exactive Plus

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Testis, Myeloblast, Peripheral Blood, Epithelial Cell, Breast

DISEASE(S): Acute Myeloid Leukemia,Embryonal Testis Carcinoma,Breast Cancer

SUBMITTER: Maruan Hijazi

LAB HEAD: Pedro Cutillas

PROVIDER: PXD018873 | Pride | 2022-04-25

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 360

Similar Datasets

Project description:The first clinical trial testing the combination of targeted therapy with a BRAF inhibitor vemurafenib and immunotherapy with a CTLA-4 antibody ipilimumab was terminated early due to significant liver toxicities, possibly due to paradoxical activation of the MAPK pathway by BRAF inhibitors in tumors with wild type BRAF. MEK inhibitors can potentiate the MAPK inhibition in tumor, while potentially alleviating the unwanted paradoxical MAPK activation. With a mouse model of syngeneic BRAFV600E driven melanoma (SM1), we tested whether the addition of the MEK inhibitor trametinib would enhance the immunosensitization effects of the BRAF inhibitor dabrafenib. Combination of dabrafenib and trametinib with pmel-1 adoptive cell transfer (ACT) showed complete tumor regression. Bioluminescent imaging and tumor infiltrating lymphocyte (TIL) phenotyping showed increased effector infiltration to tumors with dabrafenib, trametinib or dabrafenib plus trametinib with pmel-1 ACT combination. Intracellular IFN gamma staining of the TILs and in vivo cytotoxicity studies showed trametinib was not detrimental to the effector functions in vivo. Dabrafenib increased tumor associated macrophages and T regulatory cells (Tregs) in the tumors, which can be overcome by addition of trametinib. Microarray analysis revealed increased melanoma antigen, MHC expression, and global immune-related gene upregulation with the triple combination therapy. Given the up-regulation of PD-L1 seen with dabrafenib and/or trametinib combined with antigen specific ACT, we tested the triple combination of dabrafenib, trametinib with anti-PD1 therapy, and observed superior anti-tumor effect to SM1 tumors. Our findings support the testing of these combinations in patients with BRAFV600E mutant metastatic melanoma. SM1 tumors were implanted into C57BL/6 mice. Mice were treated by ACT of pmel-1 splenocytes or C57BL/6 splenocytes as control. Pmel-1 treated mice were additionally treated with either vehicle, dabrafenib, trametinib, or combination of both drugs and control mice were treated with vehicle or combination of both drugs.

			Action	DRS
	F008364.mzid.gz	Mzid
	F008364.pride.mztab.gz	Mztab
	F008365.mzid.gz	Mzid
	F008365.pride.mztab.gz	Mztab
	F008367.mzid.gz	Mzid

Dataset Information

EEF2K activity determines synergy to PI3K and MEK inhibitors in combination in cancer cells

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets